HCV
MCID: HPT073
MIFTS: 72

Hepatitis C Virus (HCV)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis C Virus

MalaCards integrated aliases for Hepatitis C Virus:

Name: Hepatitis C Virus 56
Hepatitis C Virus, Susceptibility to 56 29 6 39
Hepatitis C Virus Infection, Response to Therapy of 56 29 6
Hepatitis C Virus, Response to Therapy of 56
Hepatitis C Virus, Resistance to 56
Resistance to Hepatitis C Virus 6
Hcv, Susceptibility to 56
Hcv 56

Classifications:



External Ids:

OMIM 56 609532

Summaries for Hepatitis C Virus

OMIM : 56 HCV, which is principally transmitted by blood, infects about 3% of the world's population. HCV infection causes acute hepatitis, which is self-resolving in 20 to 50% of cases but does not confer permanent immunity. In 50 to 80% of cases, HCV infection becomes chronic and results in chronic hepatitis, cirrhosis, and hepatocellular carcinoma. As a result, HCV infection is a leading killer worldwide and the most common cause of liver failure in the U.S. HCV is opportunistic in individuals infected with human immunodeficiency virus (HIV; see 609423), approximately 25% of whom are coinfected with HCV. HCV infection is also associated with cryoglobulinemia (see 123550), a B-lymphocyte proliferative disorder (Pawlotsky, 2004; Chisari (2005); Pileri et al., 1998). (609532)

MalaCards based summary : Hepatitis C Virus, also known as hepatitis c virus, susceptibility to, is related to hepatitis c and hepatitis. An important gene associated with Hepatitis C Virus is IFNG (Interferon Gamma), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and JAK-STAT signaling pathway. The drugs Methadone and Emtricitabine have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and t cells, and related phenotypes are Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection and liver/biliary system

Wikipedia : 74 The hepatitis C virus (HCV) is a small (55-65 nm in size), enveloped, positive-sense single-stranded RNA... more...

Related Diseases for Hepatitis C Virus

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis C Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1059)
# Related Disease Score Top Affiliating Genes
1 hepatitis c 33.7 SCARB1 KRT8 KRT18 IFNL4 IFNG IFI27
2 hepatitis 32.6 SCARB1 PSMA7 KRT8 KRT18 IFNL4 IFNG
3 viral hepatitis 32.4 KRT8 KRT18 IFNL3 IFNG
4 cryptogenic cirrhosis 31.4 KRT8 KRT18
5 autoimmune hepatitis 31.4 PTPRC KRT8 KRT18
6 west nile virus 31.2 SPCS1 CLEC4M CCR5
7 human immunodeficiency virus infectious disease 31.2 PTPRC IFNG CLEC4M CCR5
8 immune deficiency disease 31.1 PTPRC IFNG CLEC4M CCR5
9 encephalitis 30.6 SPCS1 PTPRC DDX3X CLEC4M CCR5
10 west nile encephalitis 30.3 CLEC4M CCR5
11 west nile fever 30.2 CLEC4M CCR5
12 sarcoidosis 1 30.1 PTPRC IFNG CCR5
13 recurrent hepatitis c virus induced liver disease in liver transplant recipients 12.5
14 hepatocellular carcinoma 11.9
15 cryoglobulinemia, familial mixed 11.8
16 lichen planus 11.8
17 polyarteritis nodosa 11.7
18 immunotactoid glomerulopathy 11.7
19 fibrillary glomerulonephritis 11.7
20 gianotti crosti syndrome 11.3
21 immunotactoid or fibrillary glomerulopathy 11.3
22 liver cirrhosis 11.3
23 liver disease 11.3
24 cryoglobulinemia 11.1
25 hepatitis b 11.0
26 vasculitis 11.0
27 glomerulonephritis 11.0
28 end stage renal disease 10.8
29 fatty liver disease, nonalcoholic 1 10.8
30 hepatitis a 10.8
31 membranoproliferative glomerulonephritis 10.8
32 b-cell lymphoma 10.8
33 lymphoma 10.8
34 viral infectious disease 10.8
35 human immunodeficiency virus type 1 10.8
36 vaccinia 10.8
37 porphyria 10.8
38 purpura 10.8
39 porphyria cutanea tarda 10.8
40 chronic kidney disease 10.7
41 hemophilia 10.7
42 fatty liver disease 10.7
43 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.7
44 autoimmune disease 10.7
45 alcohol use disorder 10.7
46 kidney disease 10.7
47 lymphoma, hodgkin, classic 10.7
48 lymphoma, non-hodgkin, familial 10.7
49 syphilis 10.7
50 thrombocytopenia 10.7

Graphical network of the top 20 diseases related to Hepatitis C Virus:



Diseases related to Hepatitis C Virus

Symptoms & Phenotypes for Hepatitis C Virus

Clinical features from OMIM:

609532

GenomeRNAi Phenotypes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 8.32 HM13

MGI Mouse Phenotypes related to Hepatitis C Virus:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.17 CCR5 HM13 IFNG KRT18 KRT8 PTPRC

Drugs & Therapeutics for Hepatitis C Virus

Drugs for Hepatitis C Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 421)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methadone Approved Phase 4 76-99-3 4095
2
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
3
Insulin glulisine Approved Phase 4 207748-29-6
4
Insulin glargine Approved Phase 4 160337-95-1
5
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
6
Mycophenolic acid Approved Phase 4 24280-93-1 446541
7
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
8
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
Fosamprenavir Approved Phase 4 226700-79-4 131536
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
Polyestradiol phosphate Approved Phase 4 28014-46-2
13
Promethazine Approved, Investigational Phase 4 60-87-7 4927
14
Histamine Approved, Investigational Phase 4 51-45-6 774
15
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
16
Metformin Approved Phase 4 657-24-9 14219 4091
17
Nelfinavir Approved Phase 4 159989-64-7 64143
18
Zidovudine Approved Phase 4 30516-87-1 35370
19
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
20
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
21
Cobicistat Approved Phase 4 1004316-88-4
22
Didanosine Approved Phase 4 69655-05-6 50599
23
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
24
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
25
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
26
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
27 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
28
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
29
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
30
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
31
Colchicine Approved Phase 4 64-86-8 2833 6167
32
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
33
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
34
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
35
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
36
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
37
Lenvatinib Approved, Investigational Phase 4 417716-92-8
38
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
39
Lopinavir Approved Phase 4 192725-17-0 92727
40
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
41
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
42
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
43
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
44
Nevirapine Approved Phase 4 129618-40-2 4463
45
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
46
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
47
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
48
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
49
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
50 Atazanavir Sulfate Phase 4

Interventional clinical trials:

(show top 50) (show all 1426)
# Name Status NCT ID Phase Drugs
1 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
2 An Open-Label Study to Evaluate Long-Term Outcomes With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Fertile Women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection Unknown status NCT02950870 Phase 4 Ombitasvir-Paritaprevir-Ritonavir;Dasabuvir;Ribavirin
3 Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
4 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care Unknown status NCT03364725 Phase 4 Glecaprevir-pibrentasvir
5 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
6 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4
7 Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant Unknown status NCT03359746 Phase 4 Grazoprevir/Elbasvir
8 Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
9 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
10 Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860 Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
11 Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
12 An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
13 Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney Unknown status NCT03296930 Phase 4 Sofosbuvir 400 MG Oral Tablet,;Ombitasvir/paritaprevir/ritonavir
14 A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes Unknown status NCT02461745 Phase 4 ombitasvir, paritaprevir/r, dasabuvir + ribavirin;ombitasvir, paritaprevir/r, dasabuvir
15 Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo β in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4 Unknown status NCT00526448 Phase 4 ribavirin;ribavirin;Peginterferon alfa-2a;epoetin beta
16 An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
17 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
18 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
19 The Employing of the Bio-Hep-B PreS1/PreS2/S Hepatitis B Virus (HBV) Vaccine in New Born Babies From HBV Positive Palestinian Mothers Unknown status NCT01133184 Phase 4
20 Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
21 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
22 An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Effectiveness of 36 vs 48 Wks PegIntron Plus Ribavirin Treatment for HCV Patients Without Rapid Virologic Response(RVR) But With Undetectable HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
23 Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
24 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
25 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
26 Generic Velpatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Completed NCT03250910 Phase 4 Sofosbuvir and Velpatasvir;Ribavirin
27 A Multi-Site, Open-Label, Partially-Randomized Trial of the Efficacy and Safety of Fixed Dose Elbasvir/Grazoprevir (EBR/GZR) Based Regimens in French Subjects With Chronic Hepatitis C Virus (HCV) Genotype 4 Infection Completed NCT03111108 Phase 4 EBR/GZR (50 mg/100 mg) FDC
28 Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection Completed NCT01097395 Phase 4 ribavirin
29 A Multicenter Study Evaluating the Efficacy and Safety of 12 Weeks Versus 24 Weeks Peginterferon Alfa-2a 40KD Combination Therapy With Ribavirin in Interferon Naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Completed NCT00143000 Phase 4 Peginterferon alfa-2a 40KD and Ribavirin
30 A Prospective, Single-center, Open-label, Pilot Study to Investigate the Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients. Completed NCT01469884 Phase 4 Everolimus;Cyclosporine;Tacrolimus
31 Randomized Clinical Trial to Assess the Effectiveness of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 1 (TNT-1 Study) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
32 A Pilot Study to Evaluate Anti-Hepatitis C Virus Effect of Maraviroc in Patients Co-infected With Human Immunodeficiency Virus (HIV) and Hepatitis C Completed NCT02881762 Phase 4 Maraviroc
33 Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers Completed NCT01846455 Phase 4 2.0mg Buprenorphine/0.5mg Naloxone;Promethazine
34 A Study of the Antiviral Activity of Metformin as an Anti-Hepatitis C Virus Agent in Patients With Chronic Hepatitis C Virus Infection Completed NCT02972723 Phase 4 Metformin
35 Study of the Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With and Without Post-hepatitis C Cirrhosis Completed NCT02992457 Phase 4 Sofosbuvir;Ribavirin;Pegylated-interferon alfa-2a;Simeprevir;Daclatasvir;Ritaprevir, paritaprevir, ombetasvir;Sofosbuvir and Ledipasvir;Salvage therapy
36 Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir Completed NCT01222611 Phase 4 Fosamprenavir
37 A Phase Iv Single-Arm Open-Label Non-Randomized Study To Evaluate The Safety And Pharmacokinetics Of Nelfinavir (Viracept, A430) 1250mg Twice Daily (250mg Or 625mg Forms) With Lamivudine/Zidovudine (Combivir) Background Therapy In Hiv/Hepatitis C Virus (Hcv) Co-Infected Subjects With Hepatic Dysfunction. Completed NCT00141284 Phase 4 nelfinavir 1,250 mg twice daily;Zidovudine 300 mg twice daily;Lamivudine 150 mg twice daily
38 Interferon Alfa Sensitivity in HIV/HCV Coinfected Persons Before and After Antiretroviral Therapy Completed NCT01285050 Phase 4 Antiretroviral therapy (ART);raltegravir;Emtricitabine and tenofovir disoproxil fumarate
39 Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World Completed NCT02964091 Phase 4 sofosbuvir/ledipasvir
40 A Pilot Study to Assess the Feasibility of Hepatitis C Virus (HCV) Treatment as Prevention With Interferon-free Direct Acting Antivirals (DAAs) in the Prison Setting Completed NCT02064049 Phase 4 Sofosbuvir/velpatasvir
41 Role of Rapid Virologic Response in Determining Treatment Duration of Peginterferon Alfa-2b/Ribavirin in Chronic Hepatitis C Genotype 4 Completed NCT00277862 Phase 4 Pegylated IFN- alpha 2b;Ribavirin
42 Tailored Treatment of Hepatitis C Genotype 1 Completed NCT00910975 Phase 4 Peg-interferon-alfa2a (Pegasys);Ribavirin (Copegus)
43 An Open Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Completed NCT04291729 Phase 4 Ganovo+ritonavir+/-Interferon nebulization
44 An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Completed NCT04345276 Phase 4 Danoprevir+Ritonavir
45 LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients Completed NCT02631772 Phase 4 Sofosbuvir/Ledipasvir x 12 weeks;Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks
46 Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 2 Infection Completed NCT02482077 Phase 4 SOF+RBV;SOF+DCV;LDV/SOF
47 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
48 Treatment of Acute Hepatitis C Virus in HIV Co-Infection Completed NCT00845676 Phase 4 Pegylated interferon alfa-2a + Ribavirin
49 Influence of Marker of Insulin Resistance Upon HCV Treatment Responses to PEG Intron and Rebetol Therapy Completed NCT00351871 Phase 4 PEG-Intron Plus REBETOL
50 Low Dose Treatment of Ribavirin in Combination With PEG-IFN Alfa-2b in CHC Patients With genotype1 High Viral Load and Low Body Weight Completed NCT00686777 Phase 4 Ribavirin

Search NIH Clinical Center for Hepatitis C Virus

Genetic Tests for Hepatitis C Virus

Genetic tests related to Hepatitis C Virus:

# Genetic test Affiliating Genes
1 Hepatitis C Virus, Susceptibility to 29 CCR5 IFNG IFNL3 PTPRC
2 Hepatitis C Virus Infection, Response to Therapy of 29

Anatomical Context for Hepatitis C Virus

MalaCards organs/tissues related to Hepatitis C Virus:

40
Liver, Testes, T Cells, Kidney, B Cells, Bone, Thyroid

Publications for Hepatitis C Virus

Articles related to Hepatitis C Virus:

(show top 50) (show all 30045)
# Title Authors PMID Year
1
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. 61 6 56
17215375 2007
2
Altered CD45 expression in C77G carriers influences immune function and outcome of hepatitis C infection. 56 6
16505159 2006
3
The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. 56 6
15863470 2005
4
MCPIP1 suppresses hepatitis C virus replication and negatively regulates virus-induced proinflammatory cytokine responses. 56 61
25225661 2014
5
IPS-1 is essential for type III IFN production by hepatocytes and dendritic cells in response to hepatitis C virus infection. 56 61
24532585 2014
6
A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication. 56 61
24055031 2013
7
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. 61 56
23291588 2013
8
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. 61 56
22231557 2012
9
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. 61 56
21516087 2011
10
Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. 61 56
20935628 2010
11
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. 61 56
20173735 2010
12
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. 56 61
19965718 2010
13
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. 56 61
19759533 2009
14
A genome-wide genetic screen for host factors required for hepatitis C virus propagation. 61 56
19717417 2009
15
Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. 61 56
17804490 2007
16
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. 56 61
17325668 2007
17
Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. 56 61
16299033 2006
18
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. 61 56
16141076 2005
19
Unscrambling hepatitis C virus-host interactions. 56 61
16107831 2005
20
Unravelling hepatitis C virus replication from genome to function. 61 56
16107832 2005
21
Evasion of intracellular host defence by hepatitis C virus. 61 56
16107833 2005
22
Adaptive immune responses in acute and chronic hepatitis C virus infection. 56 61
16107834 2005
23
Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. 61 56
15893726 2005
24
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. 61 56
15297676 2004
25
Pathophysiology of hepatitis C virus infection and related liver disease. 61 56
15036326 2004
26
Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. 61 56
12702807 2003
27
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. 56 61
12634366 2003
28
L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. 61 56
12676990 2003
29
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. 56 61
12356718 2002
30
Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. 56 61
12186904 2002
31
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. 56 61
11781363 2002
32
Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. 61 56
11781364 2002
33
Identification of eIF2Bgamma and eIF2gamma as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach. 56 61
10900014 2000
34
Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation. 56 61
10675342 2000
35
Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. 61 56
10609818 1999
36
Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. 56 61
10535997 1999
37
Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. 61 56
10390359 1999
38
NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. 61 56
10318918 1999
39
Binding of hepatitis C virus to CD81. 61 56
9794763 1998
40
Interferon-inducible protein SCOTIN interferes with HCV replication through the autolysosomal degradation of NS5A. 56
26868272 2016
41
RACK1 controls IRES-mediated translation of viruses. 56
25416947 2014
42
IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. 56
24752298 2014
43
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. 56
23712427 2013
44
A disease-associated polymorphism alters splicing of the human CD45 phosphatase gene by disrupting combinatorial repression by heterogeneous nuclear ribonucleoproteins (hnRNPs). 6
21507955 2011
45
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. 56
20547162 2010
46
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. 56
19749757 2009
47
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. 56
19749758 2009
48
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. 56
19684573 2009
49
An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population. 6
19111528 2009
50
Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B. 6
19017985 2008

Variations for Hepatitis C Virus

ClinVar genetic disease variations for Hepatitis C Virus:

6 (show all 11) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IFNG NM_000619.2(IFNG):c.-893C>GSNV drug response 14725 rs2069707 12:68554288-68554288 12:68160508-68160508
2 PTPRC PTPRC, 77C-GSNV risk factor 14456
3 KRT8 NM_002273.4(KRT8):c.160T>C (p.Tyr54His)SNV Uncertain significance 14631 rs57749775 12:53298606-53298606 12:52904822-52904822
4 KRT8 NM_002273.4(KRT8):c.187A>G (p.Ile63Val)SNV Benign/Likely benign 66533 rs59536457 12:53298579-53298579 12:52904795-52904795
5 CCR5 NM_000579.3(CCR5):c.554_585del (p.Ser185fs)deletion Benign 8184 rs333 3:46414944-46414975 3:46373453-46373484
6 KRT18 NM_000224.3(KRT18):c.1230C>G (p.Thr410=)SNV not provided 56165 rs386834225 12:53346563-53346563 12:52952779-52952779
7 KRT18 NM_000224.3(KRT18):c.282C>T (p.Tyr94=)SNV not provided 56166 rs386834224 12:53343239-53343239 12:52949455-52949455
8 KRT8 NM_002273.4(KRT8):c.1033G>T (p.Ala345Ser)SNV not provided 56168 rs386834221 12:53292632-53292632 12:52898848-52898848
9 KRT8 NM_002273.4(KRT8):c.1412G>A (p.Gly471Glu)SNV not provided 56170 rs386834222 12:53291252-53291252 12:52897468-52897468
10 KRT18 NM_000224.3(KRT18):c.134G>C (p.Arg45Pro)SNV not provided 56167 rs200221269 12:53343091-53343091 12:52949307-52949307
11 KRT8 NM_002273.4(KRT8):c.1340C>T (p.Ala447Val)SNV not provided 56169 rs386834223 12:53291324-53291324 12:52897540-52897540

Cosmic variations for Hepatitis C Virus:

9 (show top 50) (show all 15388)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97724722 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 6
2 COSM94436083 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 6
3 COSM94063771 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 6
4 COSM88264637 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 6
5 COSM131494492 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.1159A>G p.M387V 22:29049340-29049340 6
6 COSM102131817 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 6
7 COSM113317148 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 6
8 COSM128686611 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.1072T>A p.F358I 19:36891962-36891962 6
9 COSM123949383 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 6
10 COSM86004822 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 6
11 COSM139729931 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 6
12 COSM91868668 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 6
13 COSM91880764 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.2171-78T>G p.? 19:30534769-30534769 6
14 COSM94799980 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 6
15 COSM90582798 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 6
16 COSM87577038 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 6
17 COSM151538615 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.253+23785G>T p.? 2:179745718-179745718 6
18 COSM111609487 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1444C>G p.L482V 16:89734008-89734008 6
19 COSM92353291 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 6
20 COSM95253159 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 6
21 COSM94505616 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 6
22 COSM89943752 ZMYM4 liver,NS,carcinoma,hepatocellular carcinoma c.86-8201G>T p.? 1:35350724-35350724 6
23 COSM101398456 ZIC2 liver,NS,carcinoma,hepatocellular carcinoma c.-18C>T p.? 13:99982047-99982047 6
24 COSM92703312 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 6
25 COSM92032561 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221= 14:67807621-67807621 6
26 COSM84360265 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.1979+14C>A p.? 5:32395145-32395145 6
27 COSM84362097 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 6
28 COSM85178149 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 6
29 COSM87884183 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 6
30 COSM127392053 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 6
31 COSM149268658 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 6
32 COSM149328017 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 6
33 COSM149281099 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 6
34 COSM144309108 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 6
35 COSM87420403 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 6
36 COSM98996636 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 6
37 COSM92255466 ZC3H15 liver,NS,carcinoma,hepatocellular carcinoma c.*55T>G p.? 2:186508788-186508788 6
38 COSM85044193 ZC3H14 liver,NS,carcinoma,hepatocellular carcinoma c.*10873G>A p.? 14:88622624-88622624 6
39 COSM106743522 ZBTB7B liver,NS,carcinoma,hepatocellular carcinoma c.*635G>C p.? 1:155017320-155017320 6
40 COSM93795261 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 6
41 COSM103188148 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 6
42 COSM91488114 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 6
43 COSM95291738 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 6
44 COSM107993551 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2383A>G p.I795V 8:80519295-80519295 6
45 COSM107993152 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2208A>G p.T736= 8:80518852-80518852 6
46 COSM86073785 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 6
47 COSM142300159 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1580A>G p.N527S 8:63187582-63187582 6
48 COSM90849676 YOD1 liver,NS,carcinoma,hepatocellular carcinoma c.*157T>C p.? 1:207048863-207048863 6
49 COSM90620829 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 6
50 COSM86902201 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167= 3:183722100-183722100 6

Expression for Hepatitis C Virus

LifeMap Discovery
Genes differentially expressed in tissues of Hepatitis C Virus patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CXCL10 chemokine (C-X-C motif) ligand 10 Liver + 4.26 0.000
2 CXCL11 chemokine (C-X-C motif) ligand 11 Liver + 3.57 0.000
3 LOC553137 uncharacterized LOC553137 Liver - 3.21 0.000
4 CXCL9 chemokine (C-X-C motif) ligand 9 Liver + 3.07 0.000
Search GEO for disease gene expression data for Hepatitis C Virus.

Pathways for Hepatitis C Virus

GO Terms for Hepatitis C Virus

Cellular components related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bicellular tight junction GO:0005923 9.33 CLDN9 CLDN6 CLDN1
2 apicolateral plasma membrane GO:0016327 8.96 KRT8 CLDN6
3 cell periphery GO:0071944 8.8 PTPRC KRT8 KRT18

Biological processes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.92 IFNL4 IFNL3 IFI27 DDX3X CLEC4M
2 tumor necrosis factor-mediated signaling pathway GO:0033209 9.71 PSMA7 KRT8 KRT18
3 defense response to virus GO:0051607 9.65 PTPRC IFNL4 IFNL3 IFNG IFI27
4 bicellular tight junction assembly GO:0070830 9.58 CLDN9 CLDN6 CLDN1
5 cell-cell junction organization GO:0045216 9.54 CLDN9 CLDN6 CLDN1
6 positive regulation of immune response GO:0050778 9.51 IFNL4 IFNL3
7 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.5 CLDN9 CLDN6 CLDN1
8 virion assembly GO:0019068 9.49 TBC1D20 SPCS1
9 signal peptide processing GO:0006465 9.48 SPCS1 HM13
10 viral process GO:0016032 9.47 TBC1D20 SCARB1 PTPRC PSMA7 KRT8 KRT18
11 hepatocyte apoptotic process GO:0097284 9.46 KRT8 KRT18
12 extrinsic apoptotic signaling pathway GO:0097191 9.46 KRT8 KRT18 IFNG IFI27
13 regulation of phagocytosis GO:0050764 9.43 SCARB1 PTPRC
14 viral entry into host cell GO:0046718 9.35 SCARB1 CLEC4M CLDN9 CLDN6 CLDN1

Molecular functions related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.19 TBC1D20 SPCS1 SCARB1 PTPRC PSMA7 PNKD
2 hydrolase activity GO:0016787 9.87 SPCS1 PTPRC PSMA7 PNKD HM13 DDX3X
3 identical protein binding GO:0042802 9.56 SCARB1 PSMA7 IFI27 CLDN9 CLDN6 CLDN1
4 structural molecule activity GO:0005198 9.46 KRT18 CLDN9 CLDN6 CLDN1
5 virus receptor activity GO:0001618 9.1 SCARB1 CLEC4M CLDN9 CLDN6 CLDN1 CCR5

Sources for Hepatitis C Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....